Evinacumab
Based on 1 publication(s) in Google Scholar
Evinacumab (REGN1500) is a human anti-ANGPTL3 (angiopoietin-like protein 3) monoclonal antibody (IgG4 class antibody). Evinacumab reduces plasma lipids in dyslipidemic mice by blocking ANGPTL3. Evinacumab can be used in studies of homozygous familial hypercholesterolaemia (HoFH), refractory hypercholesterolaemia (both familial and non-familial) and severe hypertriglyceridaemia.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.24%
- CAS No.: 1446419-85-7
- Masse moléculaire:144.5 kDa
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Evinacumab
More
Activité biologique
Human IgG4 kappa
Human
ANGPTL3
Evinacumab (25 mg/kg; s.c.; once weekly for 8 weeks) lowers serum TG and cholesterol levels in dyslipidemic C57Bl/6 mice[1].
Evinacumab (10 mg/kg; s.c.; single) lowers serum HDL-C by an EL-dependent mechanism in Lipg-/- mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male C57Bl/6 mice (8-week-old)[1].
-
Dosage:10 mg/kg
-
Administration:Subcutaneous injection, single.
-
Result:Caused a rapid reduction in TG levels with the maximal mean level of serum TG 55% lower than control group, and reduced 26% levels of TC.
Significantly reduced VLDL-TG, VLDL-cholesterol, and HDL-C levels.
Increased postheparin plasma LPL and improved lipid tolerance.
-
Animal Model:Male C57Bl/6 mice (8-week-old; on a high-fat high-cholesterol diet)[1].
-
Dosage:25 mg/kg
-
Administration:Subcutaneous injection, once weekly for 8 weeks.
-
Result:Led to a marked and sustained reduction in circulating TG levels (up to 53%).
Significantly reduced levels of TC (up to 35%) and LDL-C (up to 45%).
-
Animal Model:Lipg-/- mice[1].
-
Dosage:10 mg/kg
-
Administration:Subcutaneous injection, single.
-
Result:Blocked the inhibitory action of ANGPTL3 on EL with an IC50 value of 96 nM.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG4 kappa
ELISA, FACS, Functional assay
-
Immobilized huANGPTL3-c-his, can bind Evinacumab. The EC50 for this effect is 6.517 ng/mL.
Chemical Information
-
CAS No. 1446419-85-7
-
Appearance Liquid
-
Masse moléculaire 144.5 kDa
-
Color Colorless to light yellow
-
SMILES
[Evinacumab]
-
Synonyms
REGN1500
-
Livraison
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
JCI Insight
Angiopoietin-like 8 governs osteoblast-adipocyte lineage commitment during skeletal aging. [Abstract]2025 Oct 21:e189371. PMID: 41118261
Pureté et documentation
-
Fiche technique (261 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Evinacumab Related Classifications
HY-P99194 Related Classifications
Powered by Bioz